TY - JOUR
T1 - Biomarkers of eosinophil involvement in allergic and eosinophilic diseases
T2 - Review of phenotypic and serum markers including a novel assay to quantify levels of soluble Siglec-8
AU - Na, Ho Jeong
AU - Hamilton, Robert G.
AU - Klion, Amy D.
AU - Bochner, Bruce S.
N1 - Funding Information:
We thank Sherry Hudson for technical assistance. This work was supported by grant AI72265 from the National Institutes of Health . Dr. Bochner received support as a Cosner Scholar in Translational Research from Johns Hopkins University. This work was also funded in part by the Division of Intramural Research, NIAID, NIH.
PY - 2012/9/28
Y1 - 2012/9/28
N2 - There remains considerable controversy in the management of eosinophilic disorders, mainly due to a paucity of information regarding the clinical interpretation of total blood eosinophil counts versus surface activation markers versus eosinophil-derived or eosinophil-influencing mediator levels. Regrettably, few tests have been validated that define a unique clinical or prognostic phenotype that is more useful than simply monitoring total blood eosinophil counts. In this manuscript, phenotypic (cell surface) markers, along with serum and tissue-based markers that have been examined in the context of disease activity, are reviewed. We also report the development of a novel assay for detecting soluble Siglec-8 (sSiglec-8), a protein likely derived largely from eosinophils, as a potential serum biomarker. The assay consists of a competitive ELISA using a recombinant Siglec-8-Fc fusion protein. The goal of this preliminary study was to determine if sSiglec-8 is a useful biomarker that differentiates among patients with various eosinophil-associated diseases. In the final analysis, it is fair to say that further research is sorely needed to fully understand and validate the utility of various biomarkers, including sSiglec-8, before their use in clinical practice can be recommended with confidence.
AB - There remains considerable controversy in the management of eosinophilic disorders, mainly due to a paucity of information regarding the clinical interpretation of total blood eosinophil counts versus surface activation markers versus eosinophil-derived or eosinophil-influencing mediator levels. Regrettably, few tests have been validated that define a unique clinical or prognostic phenotype that is more useful than simply monitoring total blood eosinophil counts. In this manuscript, phenotypic (cell surface) markers, along with serum and tissue-based markers that have been examined in the context of disease activity, are reviewed. We also report the development of a novel assay for detecting soluble Siglec-8 (sSiglec-8), a protein likely derived largely from eosinophils, as a potential serum biomarker. The assay consists of a competitive ELISA using a recombinant Siglec-8-Fc fusion protein. The goal of this preliminary study was to determine if sSiglec-8 is a useful biomarker that differentiates among patients with various eosinophil-associated diseases. In the final analysis, it is fair to say that further research is sorely needed to fully understand and validate the utility of various biomarkers, including sSiglec-8, before their use in clinical practice can be recommended with confidence.
KW - ELISA
KW - Eosinophil
KW - Granule proteins
KW - Soluble Siglec-8
UR - http://www.scopus.com/inward/record.url?scp=84864388595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864388595&partnerID=8YFLogxK
U2 - 10.1016/j.jim.2012.05.017
DO - 10.1016/j.jim.2012.05.017
M3 - Article
C2 - 22683541
AN - SCOPUS:84864388595
SN - 0022-1759
VL - 383
SP - 39
EP - 46
JO - Journal of Immunological Methods
JF - Journal of Immunological Methods
IS - 1-2
ER -